CLEAN AIR ACT INTERIM EXEMPTIONS FOR OZONE-DEPLETING SUBSTANCES
This article was originally published in The Tan Sheet
Executive Summary
CLEAN AIR ACT INTERIM EXEMPTIONS FOR OZONE-DEPLETING SUBSTANCES are available for medical products considered "potentially essential," FDA says in a notice published in the Dec. 28 Federal Register. "Because of the impending effective dates" of bans on the sale or distribution of certain "nonessential" products that either release a class I ozone- depleting substance into the environment or contain a class II ozone-depleting substance, FDA says it will "consider granting" interim exemptions "based on the filing of a petition" requesting "essential" status for a product.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning